Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Peptide Ruling Stalls
Published 1 month, 2 weeks ago
Description
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.